Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients.

[1]  K. Søndergaard,et al.  Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases , 1985, Virchows Archiv A.

[2]  C. Garbe,et al.  Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma , 2000, Melanoma research.

[3]  D. Massi,et al.  Thick cutaneous malignant melanoma: a reappraisal of prognostic factors , 2000, Melanoma research.

[4]  Martin F. Mihm,et al.  A new American Joint Committee on Cancer staging system for cutaneous melanoma , 2000, Cancer.

[5]  R. Elashoff,et al.  Individualized prognosis for melanoma patients. , 2000, Human Pathology.

[6]  D. Tyler,et al.  Analysis of prognosis and disease progression after local recurrence of melanoma , 2000, Cancer.

[7]  A. Lippold,et al.  Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? , 1999, Cancer.

[8]  M. Ross,et al.  Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Lucci,et al.  Survival of patients with melanoma of the lower extremity decreases with distance from the trunk , 1999, Cancer.

[10]  V. Kosma,et al.  Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Kosma,et al.  Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. , 1998, British Journal of Cancer.

[12]  N. Cascinelli,et al.  11 Recent developments of immunotherapy in melanoma patients.The experience of Milano National Cancer Institute , 1997 .

[13]  H. Olsson,et al.  Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985 , 1997, Cancer.

[14]  M. Berwick,et al.  Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study , 1996, Cancer.

[15]  K. Henry,et al.  Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival , 1994, Cancer.

[16]  R. Hofmann-Wellenhof,et al.  Tumor cell proliferation and motility estimates are prognostic factors in malignant melanoma. , 1993, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[17]  C. Balch,et al.  Cutaneous melanoma: prognosis and treatment results worldwide. , 1992, Seminars in surgical oncology.

[18]  C. O'brien,et al.  Experience with 998 cutaneous melanomas of the head and neck over 30 years. , 1991, American journal of surgery.

[19]  S. McCarthy,et al.  Thin malignant melanomas and recurrence potential. , 1987, Archives of surgery.

[20]  S. Retsas.  Palaeo-oncology : the antiquity of cancer , 1986 .

[21]  V. McGovern,et al.  Prognostic significance of the histological features of malignant melanoma , 1979, Histopathology.

[22]  A. Kopf,et al.  Prognostic index for malignant melanoma , 1987, JAMA.

[23]  D. Cotton.  Atlas of Tumour Pathology , 1952 .